When to Choose Aura-E™?
High risk women—with Polycystic Ovarian Syndrome (PCOS)
Avoid unnecessary treatment and protect fertility
Distinguish non-cancerous conditions (Endometriosis & Fibroids) from early signs of malignancy
Monitor your health
after during treatment
Unusual Bleeding during Periods or after Menopause
Aura-E™ Non-Invasive
Endometrial Cancer Screening Process
Step 04
Laboratory TestingYour sample will be tested for early signs of Endometrial cancer and other abnormalities
Why Aura-E™ is a Game-Changer for Women’s Health?
Non-Invasive Sample Collection
Uses naturally shed cervical cells, so
you can get screened without
invasive procedures
Early Detection of EIN+
Supports conservative management of
EIN+ (Endometrial Intraepithelial
Neoplasia)
DNA Methylation-Based Assay
Targets clinically validated
markers (CDO1 and CELF4)
for high sensitivity and
specificity.
High Clinical Accuracy
Ideal for monitoring recurrence
after treatment.
88.00%
92.00%
EIN+
Efficient Triage Tool
CE-IVD Certified
Approved for clinical use. Detects early
changes without invasive procedures
like hysteroscopy.
Aura-E™ Distinguishes Benign vs Malignant
with High Sensitivity
Endometrial Cancer
Benign Detection Rate
Detection Sensitivity (%)
Clinical Trials Insights
Multi-center clinical trials with over 7,000 patients has shown that CDO1
and CELF4 methylation detection for endometrial cancer is significantly
more effective than other methods.
What You Receive
Gynecology Consultation
Get a personalised consultation with a
gynecologist to discuss your results
and next steps.
Further Screening or Treatment
If needed, you’ll receive recommendations
for additional screening or
treatment.
